103 related articles for article (PubMed ID: 29328476)
1. Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro.
Wang X; Jiang Z; An J; Mao X; Lin F; Sun P
Mol Med Rep; 2018 Mar; 17(3):4273-4280. PubMed ID: 29328476
[TBL] [Abstract][Full Text] [Related]
2. High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
Thummarati P; Wijitburaphat S; Prasopthum A; Menakongka A; Sripa B; Tohtong R; Suthiphongchai T
World J Gastroenterol; 2012 Jan; 18(3):244-50. PubMed ID: 22294827
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome.
Bohnert BN; Daiminger S; Wörn M; Sure F; Staudner T; Ilyaskin AV; Batbouta F; Janessa A; Schneider JC; Essigke D; Kanse S; Haerteis S; Korbmacher C; Artunc F
Acta Physiol (Oxf); 2019 Dec; 227(4):e13286. PubMed ID: 31006168
[TBL] [Abstract][Full Text] [Related]
4. Moscatilin Inhibits Metastatic Behavior of Human Hepatocellular Carcinoma Cells: A Crucial Role of uPA Suppression via Akt/NF-κB-Dependent Pathway.
Yu CL; Weng MS; Chen WC; Chien KT; Chi CW; Chung CH; Huang CW; Wang PC; Chen CC; Tsai AC; Liu SC; Wang SW
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805784
[TBL] [Abstract][Full Text] [Related]
5. Non-thermal atmospheric pressure plasma inhibits thyroid papillary cancer cell invasion via cytoskeletal modulation, altered MMP-2/-9/uPA activity.
Chang JW; Kang SU; Shin YS; Kim KI; Seo SJ; Yang SS; Lee JS; Moon E; Lee K; Kim CH
PLoS One; 2014; 9(3):e92198. PubMed ID: 24667444
[TBL] [Abstract][Full Text] [Related]
6. Licochalcone A suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of MKK4/JNK via NF-κB mediated urokinase plasminogen activator expression.
Tsai JP; Hsiao PC; Yang SF; Hsieh SC; Bau DT; Ling CL; Pai CL; Hsieh YH
PLoS One; 2014; 9(1):e86537. PubMed ID: 24466137
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice.
Hinrichs GR; Weyer K; Friis UG; Svenningsen P; Lund IK; Nielsen R; Mollet G; Antignac C; Bistrup C; Jensen BL; Birn H
Acta Physiol (Oxf); 2019 Dec; 227(4):e13362. PubMed ID: 31423748
[TBL] [Abstract][Full Text] [Related]
8. Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria.
Isaksson GL; Hinrichs GR; Andersen H; Bach ML; Weyer K; Zachar R; Henriksen JE; Madsen K; Lund IK; Mollet G; Bistrup C; Birn H; Jensen BL; Palarasah Y
J Am Soc Nephrol; 2024 Apr; 35(4):410-425. PubMed ID: 38254266
[TBL] [Abstract][Full Text] [Related]
9. Investigations on the Role of the Fibrinolytic Pathway on Outflow Facility Regulation.
Hu Y; Barron AO; Gindina S; Kumar S; Chintala S; Nayyar A; Danias J
Invest Ophthalmol Vis Sci; 2019 Apr; 60(5):1571-1580. PubMed ID: 30995314
[TBL] [Abstract][Full Text] [Related]
10. Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA).
S El Salamouni N; Buckley BJ; Jiang L; Huang M; Ranson M; Kelso MJ; Yu H
J Med Chem; 2022 Feb; 65(3):1933-1945. PubMed ID: 34898192
[TBL] [Abstract][Full Text] [Related]
11. Urokinase plasminogen activator induces epithelial-mesenchymal and metastasis of pancreatic cancer through plasmin/MMP14/TGF-β axis, which is inhibited by 4-acetyl-antroquinonol B treatment.
Wu CZ; Chu YC; Lai SW; Hsieh MS; Yadav VK; Fong IH; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen JS
Phytomedicine; 2022 Jun; 100():154062. PubMed ID: 35366491
[TBL] [Abstract][Full Text] [Related]
12. The mechanical and pharmacological regulation of glioblastoma cell migration in 3D matrices.
Kaphle P; Li Y; Yao L
J Cell Physiol; 2019 Apr; 234(4):3948-3960. PubMed ID: 30132879
[TBL] [Abstract][Full Text] [Related]
13. Carotenoids in Cancer Metastasis-Status Quo and Outlook.
Koklesova L; Liskova A; Samec M; Zhai K; Abotaleb M; Ashrafizadeh M; Brockmueller A; Shakibaei M; Biringer K; Bugos O; Najafi M; Golubnitschaja O; Büsselberg D; Kubatka P
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33321708
[TBL] [Abstract][Full Text] [Related]
14. Roles of the Na
Li X; Buckley B; Stoletov K; Jing Y; Ranson M; Lewis JD; Kelso M; Fliegel L
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948058
[TBL] [Abstract][Full Text] [Related]
15. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator.
Bin Hafeez B; Adhami VM; Asim M; Siddiqui IA; Bhat KM; Zhong W; Saleem M; Din M; Setaluri V; Mukhtar H
Clin Cancer Res; 2009 Jan; 15(2):452-9. PubMed ID: 19147749
[TBL] [Abstract][Full Text] [Related]
16. circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma.
Xu L; Wang P; Li L; Li L; Huang Y; Zhang Y; Zheng X; Yi P; Zhang M; Xu M
Mol Cancer; 2023 Oct; 22(1):174. PubMed ID: 37884951
[TBL] [Abstract][Full Text] [Related]
17. Decreased fertility in female mice lacking urokinase plasminogen activator.
Laurenzi G; Fedeli V; Canipari R
Reprod Biol; 2024 Mar; 24(1):100840. PubMed ID: 38113659
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator promotes corneal epithelial migration and nerve regeneration.
Sugioka K; Nishida T; Kodama-Takahashi A; Murakami J; Fukuda M; Matsuo O; Kusaka S
Exp Eye Res; 2023 Aug; 233():109559. PubMed ID: 37385532
[TBL] [Abstract][Full Text] [Related]
19. Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface.
Gerspach J; Németh J; Münkel S; Wajant H; Pfizenmaier K
Cancer Immunol Immunother; 2006 Dec; 55(12):1590-600. PubMed ID: 16636812
[TBL] [Abstract][Full Text] [Related]
20. Mycoplasma fermentans binds to and invades HeLa cells: involvement of plasminogen and urokinase.
Yavlovich A; Katzenell A; Tarshis M; Higazi AA; Rottem S
Infect Immun; 2004 Sep; 72(9):5004-11. PubMed ID: 15321992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
